Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines.
The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for
Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos
Malaria, a disease caused by the plasmodium parasite and transmitted through the bite of infected mosquitoes, has been a long-standing global health challenge.
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver
Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne dis
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS